GlassScriptPhysician profile
Rosann Gregory
NPI 1073743431
$2,803.11
in general payments reported to CMS, 2019-2025
18 companies · $570 in 2025
The $570 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $351 · 2022: $245 · 2023: $956 · 2024: $682 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725 · Travel and Lodging: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.80 |
| Travel and Lodging | $482.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $882.13 | 2023-2024 | Watchman Access System, Watchman Flx |
| Abiomed | $354.30 | 2024-2025 | Impella |
| Abbott Laboratories | $340.73 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Astrazeneca Pharmaceuticals LP | $288.83 | 2021-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.73 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Merck Sharp & Dohme LLC | $85.59 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $82.01 | 2024-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $73.08 | 2023-2024 | Xarelto |
| Pfizer INC. | $64.61 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $51.04 | 2021-2025 | |
| Amgen INC. | $49.14 | 2023-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.74 | 2021 | |
| Chiesi USA, INC. | $29.50 | 2024 | Cleviprex, Kengreal |
| Bayer Healthcare Pharmaceuticals INC. | $24.21 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $23.91 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $20.79 | 2024 | |
| Esperion Therapeutics, INC. | $15.77 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosann Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.